Meeting
2021 ASCO Annual Meeting
Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC.
Authors
Sumanta K. Pal
Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA
Sumanta K. Pal , David F. McDermott , Bernard Escudier , Thomas E. Hutson , Camillo Porta , Elena Verzoni , Michael B. Atkins , Michael N. Needle , Brian I. Rini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02627963
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4567)
DOI
10.1200/JCO.2021.39.15_suppl.4567
Abstract #
4567
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Safety and efficacy of tivozanib in first-line metastatic renal cell carcinoma: A multicenter compassionate use study.
First Author: Umberto Basso
Poster
2024 ASCO Genitourinary Cancers Symposium
Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
First Author: Andrew Johns
Poster
2023 ASCO Annual Meeting
Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies.
First Author: Catherine Callaghan Coombs
Poster
2022 ASCO Annual Meeting
Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
First Author: Matthew J. Matasar